# Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

> **NCT00106028** · PHASE3 · COMPLETED · sponsor: **Warner Chilcott** · enrollment: 143 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **DRUG:** risedronate sodium (Actonel)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00106028
- **Lead sponsor:** Warner Chilcott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-04
- **Final completion:** 2010-03
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2013-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106028, "Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00106028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*